Submission Details
| 510(k) Number | K211649 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | May 28, 2021 |
| Decision Date | November 23, 2021 |
| Days to Decision | 179 days |
| Submission Type | Traditional |
| Review Panel | General Hospital (HO) |
| Summary | Summary PDF |
K211649 is an FDA 510(k) clearance for the PCEA Syringe Set, a Administrations Sets With Neuraxial Connectors (Class II — Special Controls, product code PWH), submitted by Baxter Healthcare Corporation (Round Lake, US). The FDA issued a Cleared decision on November 23, 2021, 179 days after receiving the submission on May 28, 2021. This device falls under the General Hospital review panel. Regulated under 21 CFR 880.5440.
| 510(k) Number | K211649 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | May 28, 2021 |
| Decision Date | November 23, 2021 |
| Days to Decision | 179 days |
| Submission Type | Traditional |
| Review Panel | General Hospital (HO) |
| Summary | Summary PDF |
| Product Code | PWH — Administrations Sets With Neuraxial Connectors |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 880.5440 |
| Definition | The Connector For Neuraxial Applications Is Intended To Facilitate Ansi/aami/iso 80369-6:2016 Compliant Neuraxial Specific Connections. |